Urocure SR

Take orally with food (milk or meals) to enhance absorption and reduce gastrointestinal upset. Swallow the capsule whole; do not crush, chew, or open the capsule.

Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or damage bacterial ribosomal proteins, DNA, RNA, and other macromolecules. This leads to the inhibition of vital biochemical processes in the bacterial cell, ultimately resulting in bacterial death.

• Patients with anuria, oliguria, or significant impairment of renal function (creatinine clearance below 60 mL/min or end-stage renal disease).
• Known hypersensitivity to nitrofurantoin.
• Pregnant patients at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent due to the possibility of hemolytic anemia in the neonate.
• Infants under one month of age.
• Patients with a history of cholestatic jaundice/hepatic dysfunction associated with previous nitrofurantoin use.
• Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Store below 30°C in a dry place, away from direct sunlight. Keep out of reach of children.

Symptoms may include vomiting and diarrhea. No specific antidote. Management involves symptomatic and supportive care, increasing fluid intake to promote urinary excretion. Hemodialysis is ineffective.

Pregnancy Category B. Avoid use at term (38-42 weeks gestation) due to risk of hemolytic anemia in neonates. Use during first and second trimesters only if clearly needed and benefits outweigh risks. Excreted in breast milk in small amounts; use with caution during lactation, monitor infant for gastrointestinal upset or hemolytic anemia, especially if infant is G6PD deficient.

• Patients with anuria, oliguria, or significant impairment of renal function (creatinine clearance below 60 mL/min or end-stage renal disease).
• Known hypersensitivity to nitrofurantoin.
• Pregnant patients at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent due to the possibility of hemolytic anemia in the neonate.
• Infants under one month of age.
• Patients with a history of cholestatic jaundice/hepatic dysfunction associated with previous nitrofurantoin use.
• Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Store below 30°C in a dry place, away from direct sunlight. Keep out of reach of children.

Symptoms may include vomiting and diarrhea. No specific antidote. Management involves symptomatic and supportive care, increasing fluid intake to promote urinary excretion. Hemodialysis is ineffective.

Pregnancy Category B. Avoid use at term (38-42 weeks gestation) due to risk of hemolytic anemia in neonates. Use during first and second trimesters only if clearly needed and benefits outweigh risks. Excreted in breast milk in small amounts; use with caution during lactation, monitor infant for gastrointestinal upset or hemolytic anemia, especially if infant is G6PD deficient.